A truncated apoptin protein variant selectively kills cancer cells
Santiago Ruiz-Martínez1, Jessica Castro1, Maria Vilanova1
1Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Universitat de Girona and Institut d'Investigació Biomèdica de Girona Josep Trueta (IdIBGi), Girona, Spain.
Abstract:
Apoptin is a nonstructural protein encoded by one of the three open reading frames of the chicken anemia virus genome. It has attracted a great deal of interest due to its ability to induce apoptosis in multiple transformed and malignant mammalian cell lines without affecting primary and non-transformed cells. However, the use of Apoptin as an anticancer drug is restricted by its strong tendency to aggregate. A number of methods to overcome this problem have been proposed, including transduction techniques to deliver the Apoptin gene into tumor cells, but all such methods have certain drawbacks. Here we describe that a truncated variant of Apoptin, lacking residues 1 to 43, is a soluble, non-aggregating protein that maintains most of the biological properties of wild-type Apoptin when transfected into cells. We show that the cytotoxic effect of this variant is also present when it is added exogenously to cancer cells, but not to normal cells. In addition to the interest this protein has attracted as a promising therapeutic strategy, it is also an excellent model to study the structural properties of Apoptin and how they relate to its mechanism of action.
Insights
A modified Apoptin protein, a chicken anemia virus nonstructural protein, effectively induces cancer cell death. This soluble variant avoids aggregation, showing promise for cancer therapy and apoptosis research.
Area of Science:
- Molecular Biology
- Virology
- Biochemistry
Background:
- Apoptin, a chicken anemia virus protein, induces apoptosis in cancer cells but aggregates, limiting its therapeutic use.
- Existing delivery methods for Apoptin have drawbacks.
Purpose of the Study:
- To develop a soluble, non-aggregating Apoptin variant with retained anticancer properties.
- To investigate the exogenous application of this variant for cancer treatment.
Main Methods:
- Truncation of Apoptin (residues 1-43 removed) to create a soluble variant.
- Transfection of the variant into cells to assess biological activity.
- Exogenous addition of the variant to cancer and normal cells to evaluate cytotoxicity.
Main Results:
- The truncated Apoptin variant is soluble and does not aggregate.
- The variant retains the ability to induce apoptosis in cancer cells upon transfection.
- Exogenous application of the variant demonstrates selective cytotoxicity against cancer cells, sparing normal cells.
Conclusions:
- A truncated Apoptin variant offers a soluble, non-aggregating alternative with therapeutic potential.
- This variant can be delivered exogenously, simplifying its application in cancer therapy.
- The variant serves as a valuable tool for studying Apoptin's structure-function relationship and apoptotic mechanisms.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
01:30Apoptosis
01:17Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...